tetano
Editor, Senior Moderator
Stem Cell Res Ther
. 2020 Sep 18;11(1):404.
doi: 10.1186/s13287-020-01849-7.
The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm
Maria Kavianpour[SUP] 1 2 [/SUP], Mahshid Saleh[SUP] 3 [/SUP], Javad Verdi[SUP] 1 [/SUP]
Affiliations
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) pandemic is quickly spreading all over the world. This virus, which is called SARS-CoV-2, has infected tens of thousands of people. Based on symptoms, the pathogenesis of acute respiratory illness is responsible for highly homogenous coronaviruses as well as other pathogens. Evidence suggests that high inflammation rates, oxidation, and overwhelming immune response probably contribute to pathology of COVID-19. COVID-19 causes cytokine storm, which subsequently leads to acute respiratory distress syndrome (ARDS), often ending up in the death of patients. Mesenchymal stem cells (MSCs) are multipotential stem cells that are recognized via self-renewal capacity, generation of clonal populations, and multilineage differentiation. MSCs are present in nearly all tissues of the body, playing an essential role in repair and generation of tissues. Furthermore, MSCs have broad immunoregulatory properties through the interaction of immune cells in both innate and adaptive immune systems, leading to immunosuppression of many effector activities. MSCs can reduce the cytokine storm produced by coronavirus infection. In a number of studies, the administration of these cells has been beneficial for COVID-19 patients. Also, MSCs may be able to improve pulmonary fibrosis and lung function. In this review, we will review the newest research findings regarding MSC-based immunomodulation in patients with COVID-19.
Keywords: COVID-19; Cytokine storm; Immune regulatory; Mesenchymal stromal cells.
. 2020 Sep 18;11(1):404.
doi: 10.1186/s13287-020-01849-7.
The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm
Maria Kavianpour[SUP] 1 2 [/SUP], Mahshid Saleh[SUP] 3 [/SUP], Javad Verdi[SUP] 1 [/SUP]
Affiliations
- PMID: 32948252
- DOI: 10.1186/s13287-020-01849-7
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) pandemic is quickly spreading all over the world. This virus, which is called SARS-CoV-2, has infected tens of thousands of people. Based on symptoms, the pathogenesis of acute respiratory illness is responsible for highly homogenous coronaviruses as well as other pathogens. Evidence suggests that high inflammation rates, oxidation, and overwhelming immune response probably contribute to pathology of COVID-19. COVID-19 causes cytokine storm, which subsequently leads to acute respiratory distress syndrome (ARDS), often ending up in the death of patients. Mesenchymal stem cells (MSCs) are multipotential stem cells that are recognized via self-renewal capacity, generation of clonal populations, and multilineage differentiation. MSCs are present in nearly all tissues of the body, playing an essential role in repair and generation of tissues. Furthermore, MSCs have broad immunoregulatory properties through the interaction of immune cells in both innate and adaptive immune systems, leading to immunosuppression of many effector activities. MSCs can reduce the cytokine storm produced by coronavirus infection. In a number of studies, the administration of these cells has been beneficial for COVID-19 patients. Also, MSCs may be able to improve pulmonary fibrosis and lung function. In this review, we will review the newest research findings regarding MSC-based immunomodulation in patients with COVID-19.
Keywords: COVID-19; Cytokine storm; Immune regulatory; Mesenchymal stromal cells.